---
title: "Veraxa Biotech files Form 3 for Interim CFO Carl von Halem"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296530272.md"
description: "Veraxa Biotech AG announced that Interim CFO Carl von Halem filed an initial Form 3 with the SEC on July 10, 2026. The filing was published via EDGAR on August 20, 2026."
datetime: "2026-08-20T20:01:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296530272.md)
  - [en](https://longbridge.com/en/news/296530272.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296530272.md)
generator: "portal-rs"
---

# Veraxa Biotech files Form 3 for Interim CFO Carl von Halem

-   Interim CFO Carl von Halem filed an initial Form 3 for Veraxa Biotech AG, dated July 10, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-009154), on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)

## Related News & Research

- [Veraxa Biotech CEO Christoph Antz reports purchase of 5,000 shares for $7,650](https://longbridge.com/en/news/297556855.md)
- [VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase](https://longbridge.com/en/news/296932909.md)
- [Veraxa Biotech reports positive in vitro proof-of-concept for antibody-oligonucleotide conjugate candidate with Secarna](https://longbridge.com/en/news/296781575.md)
- [VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision](https://longbridge.com/en/news/296815081.md)
- [Veraxa Biotech files first BiTAC-related patent applications for cancer therapy platforms](https://longbridge.com/en/news/294550628.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**